Background-Plaque radiotherapy is the most common method of managing posterior uveal melanoma but its use for iris melanoma and iris metastases has not yet been evaluated. Methods-Fourteen patients with nonresectable iris melanoma and four with iris metastasis were treated with plaque radiotherapy. The tumour response to treatment and the local side effects of the radioactive plaque were evaluated. Results-In the iris melanoma group over a mean follow up of 26 (range 6-75) months, the tumour regressed in 13 of the 14 patients (93/o) and recurred as diffuse seeding in one patient (70/%). Despite large doses of radiation given transcorneally, the cornea developed epitheliopathy, abrasion, and oedema in only one case each. The major radiation side effects were localised iris vasculopathy without glaucoma in two cases, posterior synechiae in five cases, and cataract in six cases. In the iris metastasis group, tumour regression was observed in all four patients (100%) and radiation side effects were not evident over the relatively short mean follow up period of 8 (range 4-9) months. AUl of the 14 patients with irradiated iris melanoma have remained systemically healthy without metastasis while three of the four patients with irradiated iris metastases have died of metastases from the primary neoplasm. Conclusion-Custom designed plaque radiotherapy appears to be an effective alternative method of controlling nonresectable diffuse iris melanoma and solitary iris metastasis and has relatively few side effects. (BrJ7 Ophthalmol 1995; 79: 306-312) 
seeding in one patient (70/%). Despite large doses of radiation given transcorneally, the cornea developed epitheliopathy, abrasion, and oedema in only one case each. The major radiation side effects were localised iris vasculopathy without glaucoma in two cases, posterior synechiae in five cases, and cataract in six cases. In the iris metastasis group, tumour regression was observed in all four patients (100%) and radiation side effects were not evident over the relatively short mean follow up period of 8 (range [4] [5] [6] [7] [8] [9] months. AUl of the 14 patients with irradiated iris melanoma have remained systemically healthy without metastasis while three of the four patients with irradiated iris metastases have died of metastases from the primary neoplasm. Conclusion-Custom designed plaque radiotherapy appears to be an effective alternative method of controlling nonresectable diffuse iris melanoma and solitary iris metastasis and has relatively few side effects. (BrJ7 Ophthalmol 1995; 79: 306-312) The philosophy regarding the management of melanocytic iris lesions has gradually evolved towards more conservative treatment. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In general, a non-growing iris melanocytic tumour is managed by observation, followed by local resection if growth is documented. An iris melanoma that has a diffuse growth pattern and secondary glaucoma is usually managed by enucleation. To our knowledge, plaque radiotherapy has not been employed in the management of iris melanoma despite its frequent and successful use in the management of posterior uveal melanoma. [16] [17] [18] [19] [20] Perhaps the fear of the complications of radiotherapy on the cornea, lens, and other visually vital structures has precluded the use of radiation for the more anteriorly located tumours.
Plaque radiotherapy was initially introduced for use in retinoblastoma and later evolved for use in choroidal melanoma. 16 We have been employing plaque radiotherapy for intraocular tumours for almost 20 years and we have noticed the tolerance of the sclera to high radiation doses greater than 40 000 cGy in most cases. Even in cases of anterior ciliochoroidal tumours, the corneoscleral tissues have demonstrated a remarkable resistance to the radiation. Because of these observations, we began cautiously to employ plaque radiotherapy in selected patients with non-resectable iris melanoma who declined enucleation and in patients with solitary iris metastasis who did not wish to undergo external beam radiotherapy or chemotherapy. This (Fig 1) .20 The radiation isodose curves were designed to treat the tumour base with 2 mm of tumour-free margin on all sides and to a depth estimated from the distance of the furthest portion of the tumour from the endothelium in the dilated state. Details regarding symptoms, comeal abnormalities, anterior segment inflammation and synechia, hyphaema, hypotony, glaucoma, iris abnormalities, cataract, retinopathy, and optic neuropathy were collected at the time of plaque application, within 72 hours of plaque removal, 1 month after treatment, 6 months after treatment, and at the most recent examination. The final visual acuity and the reason for the visual loss as well as the systemic status of the patients were documented.
Results
There were 568 patients with the clinical features of iris melanoma and 41 patients with iris metastases evaluated on the Ocular Oncology Service over the time period of this study. group.bmj.com on June 22, 2017 -Published by http://bjo.bmj.com/ Downloaded from ingless. The radiation dose to the optic nerve and foveola was less than 200 cGy in all cases. The radiation rate was 304 cGy/hour (tumour base), 117 cGy/hour (tumour apex), 304 cGy/hour (comeal endothelium), 61 cGy/hour (lens). There were no immediate postoperative (0-72 hours) radiation related problems such as comeal abrasion, corneal oedema, uveitis, or hyphaema. The early radiation related problems occurred within the first 6 months, were all transient, and consisted of transient comeal abrasion in one, iritis in one, hyphaema in two (Table 3) . One of the patients with hyphaema had preoperative hyphaema presumably from tumour vessels. The late radiation related problems, developing at 6 months or later, included comeal epitheliopathy in one case, localised comeal oedema in one, posterior synechia in five, focal vasculopathy and telangiectasia of the iris in two, and cataract in six cases. The corneal epitheliopathy healed with topical lubricants, the comeal oedema remained localised to the comeal periphery, and the iris vasculopathy remained stable without progression. Comeal necrosis, scleral necrosis, radiation induced glaucoma, chronic hypotony, radiation retinopathy, or radiation papillopathy did not occur. The radiation cataract was removed and an intraocular lens implant was placed without complication in two cases.
Over a mean follow up of 26 (range 6-75) months the final visual acuity was 6/6 in seven cases, 6/7 5 in one, 6/9 in one, 6/15 in one, 6/30 in one, 6/120 in one, light perception in one (Fig 5) . The major reasons for vision of 6/15 or less included radiation cataract in three cases, recurrent hyphaema in one, comeal oedema with stromal vessels in one, and pre-existing chronic macular degeneration in one case. Antiglaucoma eyedrops were employed in eight cases, seven of whom had preradiotherapy tumour induced glaucoma (Fig 5B) . All patients but one had tumour control and retention of the eye ( There have been no tumour related metastases or deaths in this group.
IRIS METASTASIS
Plaque radiotherapy was used to treat four (10%) of 41 patients with iris metastasis. The mean age of the patients was 58 years and all four were white males. Fine needle aspiration biopsy was employed to confirm the diagnosis in all four cases and the primary site was adenocarcinoma of the lung in two cases, prostate cancer in one case, and cutaneous melanoma in one case. In three of four cases the patients presented with the iris metastasis before the discovery of the primary tumour and the needle biopsy was instrumental in this regard. The preoperative visual acuity was 6/6 in two cases, 6/9 in one case, and hand motions in one case. The mean intraocular pressure was 18 (range 8-31) mm Hg. Secondary tumour related intraocular pressure elevation occurred in one case.
In three cases the tumour growth pattern was diffuse and in one it was circumscribed ( Table 1 ). The mean tumour base was 3 (range 2-4) clock hours and the mean tumour thickness was 3 (range 2-5-4) mm. The tumour quadrants involved included inferior in one case, inferonasal in one, temporal in one, and superotemporal in one. All four tumours extended from the iris root to the midzone. Tumour seeding into the anterior chamber angle was present in only one case and there were 4 clock hours of involvement.
Since the systemic evaluation by the general oncologist showed no evidence of metastasis elsewhere, the treatment preference was to use radiotherapy rather than chemotherapy. Plaque radiotherapy was selected because the metastasis was solitary in all four cases. The patient with prostatic carcinoma metastatic to the iris had already received many months of chemotherapy and hormonal therapy and was under control systemically.
The plaque shape was custom round in three cases and custom curvilinear (boomerang shaped) in two cases (Table 2) . Iodine-125 was the radioactive isotope in three cases and ruthenium-192 in one case. The mean length of treatment was 68 (range 44-89) hours to achieve a mean dose of 22 000 (range 7700-37 000) cGy to the base and 6000 (range 4000-9000) cGy to the apex of the iris metastasis. The corneal endothelium received a mean of 22000 (range 7700-37 000) cGy and the lens centre 2315 (range 440-3900) cGy. The radiation dose to the corneal epithelium varied tremendously as explained earlier in this report. The dose to the optic nerve and foveola was less than 200 cGy in all cases. The radiation rate was 323 cGy/hour (tumour base), 90 cGy/hour (tumour apex), 323 cGy/hour (corneal endothelium), 31 cGy/hour (lens). w There were no radiation related problems in this group of patients but the follow up was limited to a mean of 8 months (range 4-9 months) (Tables 2, 3). One patient was pseudophakic at the time of plaque application. The final visual acuity was 6/6 in two cases, 6/9 in one, and 6/12 in one case. melanoma also poses a therapeutic problem to the clinician as these tumours are usually extensive and the eyes are at risk of developing angle seeding and secondary glaucoma. The margins tend to be ill defined and local resection is not advocated in these cases. In many cases enucleation is the only alternative. In the 14 cases that we treated with plaque radiotherapy, we salvaged the eye in 13 cases (93%) and vision was preserved in most cases (Fig 5) . In fact, final vision was 6/15 or better in 10 cases after a mean follow up of 26 months. As shown in Figure 5 , most patients (eight cases) maintained the same or better vision postoperatively. In six cases the vision was decreased postoperatively and the visual decrease was mild (s,2 lines) in three cases and moderate (-3 lines) in three cases. The reasons for mild decreased vision after plaque radiotherapy included radiation cataract in two cases and posterior synechia in one case. The reasons for moderate decreased vision included radiation cataract in one case, recurrent hyphaemia in one case, and corneal oedema in one case.
Despite large doses of radiation to the ciliary body and angle structures, the intraocular pressure remained relatively stable (Fig 5) except in one case in which the tumour became more extensive and infiltrated the angle causing worsening of the glaucoma and necessitating enucleation. In seven cases, the patients were treated with antiglaucoma drops preoperatively and postoperatively. In one additional case, antiglaucoma drops were added after radiotherapy because of slightly worsened glaucoma. Glaucoma filtering procedure was not performed, either before or after plaque radiotherapy.28 Six patients did not require antiglaucoma measures of any type.
The cornea' tolerated the high doses of radiotherapy. Only one patient developed corneal oedema and there were no cases of corneal melt. The most predictable problem after radiotherapy of iris melanoma was radiation induced cataract. This was observed to some degree in six of 13 patients with a crystalline lens. In two cases, cataract surgery and intraocular lens implant was performed after convincing tumour regression and in the remaining four cases, surgery has been postponed. Perhaps the most worrisome problem was radiation induced vasculopathy of the iris. Radiation induced iris vasculopathy was documented in two cases, but there were no cases of diffuse iris neovascularisation. The iris vasculopathy did not result in glaucoma, but it led to transient hyphaemia in both cases. Importantly, there were no cases of radiation retinopathy or optic neuropathy. The custom design of the radioactive plaque was structured to adequately irradiate the tumour and minimise radiation effects on the retina, optic nerve, and lens.
The tumour regression in the iris melanoma group differed from the iris metastasis group. In the iris melanoma group, the tumours showed slow shrinkage in the thickness and often base measurements over a several month period, similar to that observed with choroidal melanoma. '6 In patients with iris metastasis, the tumour rapidly regressed to a small remnant or disappeared with minimal residual scarring of the iris over a 1-2 month period. The use of plaque radiotherapy is theoretically advantageous over external beam radiotherapy for solitary iris metastasis because it spares excessive radiation to the orbit and remainder of the globe and the duration of treatment with plaque radiotherapy is much shorter than external beam radiotherapy. The average plaque duration for iris metastasis extended over a mean of 21/2 days compared with 5 weeks for external beam radiotherapy.
There were no cases of metastasis or death in the group of patients with iris melanoma, but we realise that the follow up is relatively short at a mean of 26 months. 30 
